281 related articles for article (PubMed ID: 28527723)
21. RIG-I-mediated innate immune signaling in tumors reduces the therapeutic effect of oncolytic vesicular stomatitis virus.
Zhang P; Han X; Tan W; Chen D; Sun Q
Thorac Cancer; 2023 Jan; 14(3):246-253. PubMed ID: 36447430
[TBL] [Abstract][Full Text] [Related]
22. PML has a predictive role in tumor cell permissiveness to interferon-sensitive oncolytic viruses.
Sobol PT; Hummel JL; Rodrigues RM; Mossman KL
Gene Ther; 2009 Sep; 16(9):1077-87. PubMed ID: 19474810
[TBL] [Abstract][Full Text] [Related]
23. Vesicular stomatitis virus expressing interferon-β is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer.
Patel MR; Jacobson BA; Ji Y; Drees J; Tang S; Xiong K; Wang H; Prigge JE; Dash AS; Kratzke AK; Mesev E; Etchison R; Federspiel MJ; Russell SJ; Kratzke RA
Oncotarget; 2015 Oct; 6(32):33165-77. PubMed ID: 26431376
[TBL] [Abstract][Full Text] [Related]
24. Type III interferon attenuates a vesicular stomatitis virus-based vaccine vector.
Guayasamin RC; Reynolds TD; Wei X; Fujiwara M; Robek MD
J Virol; 2014 Sep; 88(18):10909-17. PubMed ID: 25008938
[TBL] [Abstract][Full Text] [Related]
25. Defective Interfering Genomes and the Full-Length Viral Genome Trigger RIG-I After Infection With Vesicular Stomatitis Virus in a Replication Dependent Manner.
Linder A; Bothe V; Linder N; Schwarzlmueller P; Dahlström F; Bartenhagen C; Dugas M; Pandey D; Thorn-Seshold J; Boehmer DFR; Koenig LM; Kobold S; Schnurr M; Raedler J; Spielmann G; Karimzadeh H; Schmidt A; Endres S; Rothenfusser S
Front Immunol; 2021; 12():595390. PubMed ID: 33995343
[TBL] [Abstract][Full Text] [Related]
26. Cancer upregulated gene 2, a novel oncogene, confers resistance to oncolytic vesicular stomatitis virus through STAT1-OASL2 signaling.
Malilas W; Koh SS; Srisuttee R; Boonying W; Cho IR; Jeong CS; Johnston RN; Chung YH
Cancer Gene Ther; 2013 Feb; 20(2):125-32. PubMed ID: 23306614
[TBL] [Abstract][Full Text] [Related]
27. Changes in Susceptibility to Oncolytic Vesicular Stomatitis Virus during Progression of Prostate Cancer.
Yu N; Puckett S; Antinozzi PA; Cramer SD; Lyles DS
J Virol; 2015 May; 89(10):5250-63. PubMed ID: 25741004
[TBL] [Abstract][Full Text] [Related]
28. Virus-Triggered ATP Release Limits Viral Replication through Facilitating IFN-β Production in a P2X7-Dependent Manner.
Zhang C; He H; Wang L; Zhang N; Huang H; Xiong Q; Yan Y; Wu N; Ren H; Han H; Liu M; Qian M; Du B
J Immunol; 2017 Aug; 199(4):1372-1381. PubMed ID: 28687662
[TBL] [Abstract][Full Text] [Related]
29. Characterization of the Impact of Oncolytic Vesicular Stomatitis Virus on the Trafficking, Phenotype, and Antigen Presentation Potential of Neutrophils and Their Ability to Acquire a Non-Structural Viral Protein.
Stegelmeier AA; Chan L; Mehrani Y; Petrik JJ; Wootton SK; Bridle B; Karimi K
Int J Mol Sci; 2020 Sep; 21(17):. PubMed ID: 32882969
[TBL] [Abstract][Full Text] [Related]
30. The Oncolytic Virus VSV-GP Is Effective against Malignant Melanoma.
Kimpel J; Urbiola C; Koske I; Tober R; Banki Z; Wollmann G; von Laer D
Viruses; 2018 Mar; 10(3):. PubMed ID: 29498639
[TBL] [Abstract][Full Text] [Related]
31. Potential of vesicular stomatitis virus as an oncolytic therapy for recurrent and drug-resistant ovarian cancer.
Heiber JF; Xu XX; Barber GN
Chin J Cancer; 2011 Dec; 30(12):805-14. PubMed ID: 22059911
[TBL] [Abstract][Full Text] [Related]
32. The VSV matrix protein inhibits NF-κB and the interferon response independently in mouse L929 cells.
Marquis KA; Becker RL; Weiss AN; Morris MC; Ferran MC
Virology; 2020 Sep; 548():117-123. PubMed ID: 32838932
[TBL] [Abstract][Full Text] [Related]
33. First-in-class small molecule potentiators of cancer virotherapy.
Dornan MH; Krishnan R; Macklin AM; Selman M; El Sayes N; Son HH; Davis C; Chen A; Keillor K; Le PJ; Moi C; Ou P; Pardin C; Canez CR; Le Boeuf F; Bell JC; Smith JC; Diallo JS; Boddy CN
Sci Rep; 2016 May; 6():26786. PubMed ID: 27226390
[TBL] [Abstract][Full Text] [Related]
34. VSV-tumor selective replication and protein translation.
Barber GN
Oncogene; 2005 Nov; 24(52):7710-9. PubMed ID: 16299531
[TBL] [Abstract][Full Text] [Related]
35. Ruxolitinib and Polycation Combination Treatment Overcomes Multiple Mechanisms of Resistance of Pancreatic Cancer Cells to Oncolytic Vesicular Stomatitis Virus.
Felt SA; Droby GN; Grdzelishvili VZ
J Virol; 2017 Aug; 91(16):. PubMed ID: 28566376
[TBL] [Abstract][Full Text] [Related]
36. Vesicular stomatitis virus as an oncolytic agent against pancreatic ductal adenocarcinoma.
Murphy AM; Besmer DM; Moerdyk-Schauwecker M; Moestl N; Ornelles DA; Mukherjee P; Grdzelishvili VZ
J Virol; 2012 Mar; 86(6):3073-87. PubMed ID: 22238308
[TBL] [Abstract][Full Text] [Related]
37. Oncolytic Therapy of Solid Tumors by Modified Vesicular Stomatitis Virus.
Gao Y
DNA Cell Biol; 2024 Feb; 43(2):57-60. PubMed ID: 38079267
[TBL] [Abstract][Full Text] [Related]
38. In silico trials predict that combination strategies for enhancing vesicular stomatitis oncolytic virus are determined by tumor aggressivity.
Jenner AL; Cassidy T; Belaid K; Bourgeois-Daigneault MC; Craig M
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33608375
[TBL] [Abstract][Full Text] [Related]
39. SARS-CoV-2 RBD protein enhances the oncolytic activity of the vesicular stomatitis virus.
Alkayyal AA; Ajina R; Cacciabue M; Alkayyal AA; Saeedi NH; Hussain Alshehry T; Kaboha F; Alotaibi MA; Zaidan N; Shah K; Alroqi F; Bakur Mahmoud A
Front Immunol; 2023; 14():1082191. PubMed ID: 36798114
[TBL] [Abstract][Full Text] [Related]
40. Vesicular stomatitis virus sensitizes immunologically cold tumors to checkpoint blockade by inducing pyroptosis.
Lin J; Liu F; Gao F; Chen Y; Wang R; Wang X; Li Y; Li Q; Sun S; Li Z; Lan Y; Lu H; Guo W; Du L; Gao F; Song D; Zhao K; Guan J; He W
Biochim Biophys Acta Mol Basis Dis; 2022 Dec; 1868(12):166538. PubMed ID: 36096276
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
